Revolutionizing the management of patients with atopic dermatitis: practical considerations

Click to increase image sizeClick to decrease image size

Declaration of interest

F Russo acted as speaker and consultant for Sanofi, AbbVie, and Novartis. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reviewer disclosures

A reviewer on this manuscript has disclosed receipt of personal honoraria from Pfizer (makes abrocitinib) and Sanofi (in part makes dupilumab). Peer reviewers on this manuscript have no other relevant financial relationships or otherwise to disclose.

Author contributions

All authors contributed to the article conception and design. Material preparation, data collection, and analysis were performed by E Camela and F Russo. The first draft of the manuscript was written by E Camela and F Russo. All authors read and approved the final manuscript.

Additional information

Funding

This paper was not funded.